Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

View Full Paper
Ask AI
Bookmark
Share

Authors

TKTariq KewanDJDragan JevremovićPGPatricia T. Greipp

Discussion

Loading...

Member takes

Overview

Real-world evaluation shows acute myeloid leukemia prognostic models impact survival outcomes, indicating key genetic factors.

Key Points

  • Overall survival in acute myeloid leukemia was significantly improved with ELN 2024 and Beat AML 2024 compared to ELN 2022.
  • Molecular data including mutations like TP53 and DNMT3A were integral to risk stratification across treatment types.
  • Analysis used multivariable Cox proportional hazards models to adjust for variables influencing outcomes in the cohort.
  • Aligning molecular risk factors with treatment strategies is vital for enhancing prognostic accuracy in acute myeloid leukemia.

Cite This Study

Kewan et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e38fhttps://doi.org/10.1182/blood-2025-996
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population2025
  2. 2Risk stratification of newly diagnosed AML receiving nonintensive treatment2025
  3. 3Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.2025
  4. 4TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT2025
  5. 5Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model2025